These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 33304621)

  • 1. Preliminary Results of the Micro-Elimination Project of Hepatitis C in a Disadvantaged Town in South-West of Romania-Orşova.
    Butaru AE; Doica IP; Gheonea DI; Rogoveanu I; Diculescu M; Oancea CN
    Curr Health Sci J; 2020; 46(3):217-221. PubMed ID: 33304621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Micro-Elimination: Updated Pathway to Global Elimination of Hepatitis C in Small Communities and Industrial Settings during the COVID 19 Pandemic.
    Butaru AE; Gheonea DI; Rogoveanu I; Diculescu M; Boicea AR; Bunescu M; Streba CT; Oancea CN
    J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C Virus Prevalence and Risk Factors in a Village in Northeastern Romania-A Population-Based Screening-The First Step to Viral Micro-Elimination.
    Huiban L; Stanciu C; Muzica CM; Cuciureanu T; Chiriac S; Zenovia S; Burduloi VM; Petrea O; Sîngeap AM; Gîrleanu I; Sfarti C; Cojocariu C; Trifan A
    Healthcare (Basel); 2021 May; 9(6):. PubMed ID: 34072635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resource Management through Artificial Intelligence in Screening Programs-Key for the Successful Elimination of Hepatitis C.
    Butaru AE; Mămuleanu M; Streba CT; Doica IP; Diculescu MM; Gheonea DI; Oancea CN
    Diagnostics (Basel); 2022 Jan; 12(2):. PubMed ID: 35204437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cross-sectional epidemiological study of HBV, HCV, HDV and HEV prevalence in the SubCarpathian and South-Eastern regions of Romania.
    Voiculescu M; Iliescu L; Ionescu C; Micu L; Ismail G; Zilisteanu D; Radasan A; Micu G; Pertache I
    J Gastrointestin Liver Dis; 2010 Mar; 19(1):43-8. PubMed ID: 20361074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The contribution of telemedicine to hepatitis C elimination in a correctional facility.
    Jiménez Galán G; Alia Alia C; Vegue González M; García Berriguete RMª; Fernández González F; Fernández Rodríguez CM; González Fernández M; Gutiérrez García ML; Losa JE; Velasco M; Moreno L; Hervás R; Delgado-Iribarren A; Palacios García-Cervigón G
    Rev Esp Enferm Dig; 2019 Jul; 111(7):550-555. PubMed ID: 31215210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Micro-elimination of hepatitis C through testing of Egyptian pregnant women presenting at delivery: implications for screening policies.
    Mostafa A; Ebeid FSE; Khaled B; Ahmed RHM; El-Sayed MH
    Trop Med Int Health; 2020 Jul; 25(7):850-860. PubMed ID: 32306545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introducing hepatitis C virus healthcare pathways in addiction care in the Netherlands with a Breakthrough project: a mixed method study.
    Kracht PAM; de Gee EA; van der Poel A; Verhagen MAMT; Hoepelman AIM; Croes EA; Arends JE
    Harm Reduct J; 2019 Jul; 16(1):45. PubMed ID: 31307470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
    Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
    J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C Virus Screening and Care: Complexity of Implementation in Primary Care Practices Serving Disadvantaged Populations.
    Turner BJ; Rochat A; Lill S; Bobadilla R; Hernandez L; Choi A; Guerrero JA
    Ann Intern Med; 2019 Dec; 171(12):865-874. PubMed ID: 31791065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents.
    Olafsson S; Tyrfingsson T; Runarsdottir V; Bergmann OM; Hansdottir I; Björnsson ES; Johannsson B; Sigurdardottir B; Fridriksdottir RH; Löve A; Hellard M; Löve TJ; Gudnason T; Heimisdottir M; Gottfredsson M
    J Intern Med; 2018 May; 283(5):500-507. PubMed ID: 29512219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Most Patients of Hepatitis C Virus Infection in India Present Late for Interferon-Based Antiviral Treatment: An Epidemiological Study of 777 Patients from a North Indian Tertiary Care Center.
    Gupta V; Kumar A; Sharma P; Bansal N; Singla V; Arora A
    J Clin Exp Hepatol; 2015 Jun; 5(2):134-41. PubMed ID: 26155041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
    Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.
    Sonderup MW; Gogela N; Nordien R; Smuts H; Korsman S; Hardie D; Spearman CW
    S Afr Med J; 2020 Jan; 110(2):112-117. PubMed ID: 32657680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies.
    van Tilborg M; Al Marzooqi SH; Wong WWL; Maan R; Vermehren J; Maasoumy B; Mazzulli T; Bolotin S; Garber G; Guerra F; Flud CR; Kowgier M; Janssen HL; de Knegt RJ; Pawlotsky JM; Cloherty GA; Duarte-Rojo A; Sarrazin C; Wedemeyer H; Feld JJ
    Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):856-864. PubMed ID: 30274834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Point-of-care testing for HCV infection: recent advances and implications for alternative screening.
    Parisi MR; Soldini L; Vidoni G; Mabellini C; Belloni T; Brignolo L; Negri S; Schlusnus K; Dorigatti F; Lazzarin A
    New Microbiol; 2014 Oct; 37(4):449-57. PubMed ID: 25387283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the Performance of Algorithms That Use Serial Hepatitis C RNA Tests to Predict Treatment Initiation and Sustained Virological Response Among Patients Infected With Hepatitis C Virus.
    Osinubi A; Harris AM; Vellozzi C; Lom J; Miller L; Millman AJ
    Am J Epidemiol; 2019 Mar; 188(3):555-561. PubMed ID: 30535062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade.
    Bregenzer A; Conen A; Knuchel J; Friedl A; Eigenmann F; Näf M; Ackle P; Roth M; Fux CA
    Swiss Med Wkly; 2017; 147():w14544. PubMed ID: 29185250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.
    Katz LH; Goldvaser H; Gafter-Gvili A; Tur-Kaspa R
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008516. PubMed ID: 22972122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.